NovaBay Historical Financial Ratios
| NBY Stock | USD 0.53 0.03 6.00% |
NovaBay Pharmaceuticals is lately reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 17.87 will help investors to properly organize and evaluate NovaBay Pharmaceuticals financial condition quickly.
NovaBay |
About NovaBay Financial Ratios Analysis
NovaBay PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate NovaBay Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on NovaBay financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across NovaBay Pharmaceuticals history.
NovaBay Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing NovaBay Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on NovaBay Pharmaceuticals sales, a figure that is much harder to manipulate than other NovaBay Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Return On Tangible Assets
A profitability metric that measures a company's ability to generate earnings from its tangible assets.Most ratios from NovaBay Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into NovaBay Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.At this time, NovaBay Pharmaceuticals' Income Quality is fairly stable compared to the past year. Intangibles To Total Assets is likely to rise to 0.15 in 2024, whereas Price To Sales Ratio is likely to drop 0.06 in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 72.3 | 50.0 | 18.81 | 17.87 | PTB Ratio | 1.43 | 0.19 | 0.26 | 0.25 |
NovaBay Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
NovaBay Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NovaBay Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 1.93 | 2.46 | 1.73 | 0.14 | 0.0584 | 0.0555 | |
| Ptb Ratio | 13.11 | 1.98 | 1.43 | 0.19 | 0.26 | 0.25 | |
| Days Sales Outstanding | 58.96 | 40.64 | 72.3 | 50.0 | 18.81 | 17.87 | |
| Book Value Per Share | 59.81 | 430.2 | 321.5 | 351.79 | 27.52 | 26.14 | |
| Free Cash Flow Yield | (0.62) | (0.19) | (0.63) | (3.3) | (4.83) | (4.59) | |
| Operating Cash Flow Per Share | (487.37) | (164.88) | (290.56) | (221.79) | (34.3) | (36.02) | |
| Stock Based Compensation To Revenue | 0.0941 | 0.0706 | 0.14 | 0.0153 | 0.0198 | 0.0188 | |
| Pb Ratio | 13.11 | 1.98 | 1.43 | 0.19 | 0.26 | 0.25 | |
| Ev To Sales | 1.49 | 1.31 | 0.91 | (0.0884) | 0.0319 | 0.0303 | |
| Free Cash Flow Per Share | (488.54) | (165.79) | (292.2) | (225.53) | (34.46) | (36.18) | |
| Roic | (2.08) | (0.5) | (0.18) | (0.45) | (1.01) | (1.06) | |
| Inventory Turnover | 3.53 | 6.53 | 0.86 | 1.93 | 2.37 | 2.12 | |
| Net Income Per Share | (644.6) | (385.53) | (207.33) | (542.15) | (80.05) | (84.05) | |
| Days Of Inventory On Hand | 103.33 | 55.9 | 423.38 | 189.42 | 153.73 | 146.04 | |
| Payables Turnover | 5.25 | 13.15 | 2.66 | 6.13 | 6.05 | 3.22 | |
| Research And Ddevelopement To Revenue | 0.0279 | 0.0287 | 0.005225 | 0.0121 | 0.004618 | 0.004387 | |
| Capex To Revenue | 0.002879 | 0.002617 | 0.006175 | 0.007776 | 0.00129 | 0.001226 | |
| Cash Per Share | 426.39 | 417.42 | 237.2 | 178.73 | 25.99 | 24.69 | |
| Pocfratio | (1.61) | (5.18) | (1.59) | (0.31) | (0.21) | (0.22) | |
| Capex To Operating Cash Flow | (0.002396) | (0.005507) | (0.005657) | (0.0168) | (0.004599) | (0.004829) | |
| Pfcf Ratio | (1.6) | (5.15) | (1.58) | (0.3) | (0.21) | (0.22) | |
| Days Payables Outstanding | 69.51 | 27.77 | 137.4 | 59.52 | 60.38 | 57.36 | |
| Roe | (10.78) | (0.9) | (0.64) | (1.54) | (2.91) | (3.05) | |
| Ev To Operating Cash Flow | (1.24) | (2.75) | (0.83) | 0.19 | (0.11) | (0.12) | |
| Pe Ratio | (1.22) | (2.21) | (2.23) | (0.13) | (0.0892) | (0.0937) | |
| Return On Tangible Assets | (0.93) | (0.23) | (0.46) | (1.18) | (1.07) | (1.12) | |
| Ev To Free Cash Flow | (1.24) | (2.74) | (0.83) | 0.19 | (0.11) | (0.12) | |
| Earnings Yield | (0.6) | (0.82) | (0.45) | (7.94) | (11.21) | (10.65) | |
| Net Debt To E B I T D A | 0.31 | 1.8 | 0.8 | 0.46 | 0.0813 | 0.0772 | |
| Current Ratio | 1.65 | 5.03 | 3.83 | 2.66 | 1.67 | 1.59 | |
| Tangible Book Value Per Share | 59.81 | 1.6K | 14.0 | 264.19 | 27.52 | 26.14 | |
| Receivables Turnover | 6.19 | 8.98 | 5.05 | 7.3 | 19.4 | 20.37 | |
| Graham Number | 931.35 | 1.9K | 1.2K | 2.1K | 222.63 | 211.5 | |
| Shareholders Equity Per Share | 59.81 | 430.2 | 321.5 | 351.79 | 27.52 | 26.14 | |
| Capex Per Share | 1.17 | 0.91 | 1.64 | 3.73 | 0.16 | 0.15 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.